Nowadays, the cobas EGFR Mutation Test v2 (Roche Molecular Systems) [21] has been approved by the FDA for the qualitative detection in plasma of exon 19 deletions or p.L858R of EGFR, to select patients with advanced NSCLC for treatment with EGFR-TKIs. This evidence concerns the gene EGFR and non-small cell lung carcinoma.